Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00383812

Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy Clinical Trial

Official title:
Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

Clinical Trial Summary

1. Primary objectives

a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV)

2. Secondary objectives

1. To assess the changes in visual acuity

2. To assess the change in lesion characteristics of PCV

- size of PCV

- fluorescein leakage

- foveal thickness

3. To investigate the safety of intravitreal Bevacizumab in patients with PCV

4. To assess the effect of intravitreal Bevacizumab on the recurrence rate and the the incidence of submacular hemorrhage in patients with PCV

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00383812
Study type Interventional
Source Asan Medical Center
Contact Sun Young Lee, MD
Phone 82-2-3010-3970
Email sunylee@amc.seoul.kr
Status Recruiting
Phase N/A
Start date May 2006
Completion date May 2008
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT01950741 - Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Phase 4
Completed NCT01469156 - Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Recruiting NCT02597855 - Comparison of the Short-term Outcomes of Intravitreal Aflibercept Injection Between Two Subtypes of Polypoidal Choroidal Vasculopathy Using Indocyanine Green Angiography N/A
Completed NCT02495181 - Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Phase 4
Active, not recruiting NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT01248117 - Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT01884597 - Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) Phase 1/Phase 2
Recruiting NCT04707027 - Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept N/A
Recruiting NCT02141308 - OCT in Rare Chorioretinal Diseases
Completed NCT01871376 - Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation Phase 4
Completed NCT00470977 - Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Phase 1/Phase 2
Completed NCT00837330 - Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy Phase 1/Phase 2
Completed NCT05229237 - Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
Not yet recruiting NCT04380974 - Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy Phase 4
Recruiting NCT02815176 - Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers N/A
Active, not recruiting NCT00344617 - Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy Phase 3
Recruiting NCT03929731 - Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
Completed NCT01023295 - Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) Phase 2
Completed NCT02821520 - Initial Versus Delayed PDT Combination With Conbercept in PCV Phase 4